In recent years, several molecular biomarker candidates have been identified in leiomyosarcoma, including the insulin-like growth factor 1 receptor (IGF1R), MDM2, TP53, fragile histidine triad (FHIT), and microRNAs (6), however, a clinical evaluation of these biomarkers was not performed. The gene discussed is IGF1R; the disease is leiomyosarcoma.